DEF 14A: ZimVie Inc. Files Proxy Statement for 2024 Annual Meeting, Outlines Executive Compensation and Corporate Governance

ZimVie Inc.'s proxy statement details proposals for the 2024 annual shareholder meeting, including director elections, auditor ratification, and executive compensation approval.

Summary

• ZimVie Inc. has released its proxy statement for the 2024 annual meeting of shareholders, scheduled for May 15, 2024.
• The proxy statement outlines three key proposals: the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for 2024, and an advisory vote on named executive officer compensation.
• The Board of Directors recommends voting for all three proposals.
• The document details the company's corporate governance framework, including board composition, independence, risk oversight, and stock ownership guidelines.
• Executive compensation is discussed, highlighting the program's objectives, elements, and alignment with shareholder interests.
• The proxy statement also includes information on director and executive officer stock ownership, related person transactions, and other relevant information for shareholders.
• A definitive agreement to sell the spine business to an affiliate of H.I.G. Capital for $375 million is expected to close in the first half of 2024.

Sentiment

Score: 6

Explanation: The document is generally neutral, providing factual information about the company's annual meeting and related matters. While there are some positive aspects highlighted, such as the company's commitment to corporate governance and shareholder engagement, there are also some challenges and risks identified, such as the company's financial performance and the ongoing transformation.

Positives

• The Board is composed of a diverse and experienced group of directors, with a majority being independent.
• The company has robust corporate governance policies and practices in place.
• Executive compensation is strongly linked to performance and shareholder value creation.
• The company has a clawback policy for incentive compensation in the event of financial restatements.
• The company prohibits hedging and pledging of company stock by directors and executives.
• The company is committed to shareholder engagement and transparency.
• The company is advancing its transformational plans to become a pure-play Dental company.

Negatives

• The company's financial performance in 2023 did not meet all targets, resulting in lower payouts under the annual incentive plan.
• The company is undergoing a significant transformation, including the sale of its spine business, which may create uncertainty.
• The company's stock price has been volatile, which may impact the value of equity-based compensation.

Risks

• General commercial risks in the medical technology/healthcare industry, such as competition and pricing pressures.
• Risks associated with the company's strategy, business model, and annual operating plan.
• Risks related to the company's operations and supply chain.
• Risks related to complex transactions, such as the sale of the spine business.
• The company's ability to successfully execute its transformation plan and achieve its strategic goals.
• The company's ability to attract and retain key personnel.
• The company's ability to comply with legal and regulatory requirements.

Future Outlook

The company is focused on becoming a pure-play dental company and expects the sale of its spine business to close in the first half of 2024.

Management Comments

• The team made a great deal of progress executing our corporate strategy while keeping our Mission at the forefront.
• We are confident about the value this will deliver to our customers and to you, our shareholders.

Industry Context

The medical technology industry is highly competitive, with companies constantly innovating and developing new products and solutions. ZimVie competes with a variety of companies in the dental and spine markets.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies such as Accuray Incorporated, Avanos Medical, Inc., Bioventus Inc., CONMED Corporation, Envista Holdings Corporation, Globus Medical, Inc., Haemonetics Corporation, ICU Medical, Inc., Integer Holdings Corporation, Integra LifeSciences Holdings Corporation, LivaNova PLC, Merit Medical Systems, Inc., Natus Medical Incorporated, Nevro Corp., NuVasive, Inc., Orthofix Medical Inc., Penumbra, Inc., and Varex Imaging Corporation.
• The company's executive compensation program is designed to be competitive with the peer group and to align with industry best practices.
• The company's corporate governance practices are consistent with those of other publicly traded companies in the medical technology industry.

Related Party Transactions

• The company has entered into various agreements with Zimmer Biomet in connection with the separation, including a Separation and Distribution Agreement, a Tax Matters Agreement, a Transition Services Agreement, an Intellectual Property Matters Agreement, a Transitional Trademark License Agreement, a Transition Manufacturing and Supply Agreement, and a Reverse Transition Manufacturing and Supply Agreement.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key proposals at the annual meeting.
• Employees may be impacted by the company's transformation plan, including the sale of the spine business.
• Customers may benefit from the company's focus on innovation and new product development.
• Suppliers and creditors may be impacted by the company's financial performance and strategic decisions.

Next Steps

• Shareholders are encouraged to review the proxy statement and vote their shares.
• The company will hold its annual meeting of shareholders on May 15, 2024.
• The company will continue to execute its strategic plan, including the sale of its spine business and the focus on its dental business.

Key Dates

Keywords

executive compensation, corporate governance, annual meeting, proxy statement, director election, auditor ratification, PwC, shareholder vote, ZimVie, spine business, dental business